Analyst Price Targets — STOK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 9:25 am | Kevin Strang | Goldman Sachs | $44.00 | $31.38 | TheFly | Stoke Therapeutics initiated with a Buy at Goldman Sachs |
| February 23, 2026 9:12 pm | — | Wolfe Research | $40.00 | $36.23 | TheFly | Stoke Therapeutics initiated with an Outperform at Wolfe Research |
| February 5, 2026 9:55 am | Yatin Suneja | Guggenheim | $60.00 | $32.00 | TheFly | Stoke Therapeutics initiated with a Buy at Guggenheim |
| January 12, 2026 2:04 pm | — | Wedbush | $36.00 | $28.14 | TheFly | Stoke Therapeutics price target raised to $36 from $32 at Wedbush |
| January 5, 2026 11:53 am | — | Canaccord Genuity | $36.00 | $30.90 | TheFly | Stoke Therapeutics price target raised to $36 from $28 at Canaccord |
| January 5, 2026 9:23 am | Keay Nakae | Loop Capital Markets | $35.00 | $30.90 | StreetInsider | Chardan Capital Markets Assumes Stoke Therapeutics (STOK) at Buy |
| December 16, 2025 11:49 am | Andrew Fein | H.C. Wainwright | $50.00 | $32.90 | StreetInsider | Stoke Therapeutics (STOK) PT Raised to $50 at H.C. Wainwright |
| December 15, 2025 1:44 pm | — | UBS | $50.00 | $32.82 | TheFly | Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright |
| November 5, 2025 2:26 pm | — | Canaccord Genuity | $28.00 | $21.42 | TheFly | Stoke Therapeutics price target raised to $28 from $24 at Canaccord |
| October 10, 2025 11:37 am | — | Needham | $35.00 | $29.90 | TheFly | Stoke Therapeutics price target raised to $35 from $22 at Needham |
Latest News for STOK
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on July 15, 2026, it granted…
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of enrollment of 162 patients…
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on June 15, 2026, it granted…
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for STOK.
U.S. House Trading
No House trades found for STOK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.